Similarly, positive outcomes were observed in a phase I/II clinical study (NCT00902044) involving the use of HER2 CAR-T cells for the treatment of 19 patients with HER2-positive sarcomas, including 16 osteosarcomas, 1 primitive neuroectodermal tumor, 1 Ewing sarcoma, and 1 protofibroblastic small round cell tumor. The gene discussed is ERBB2; the disease is osteosarcoma.